NASDAQ:RYTM Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free RYTM Stock Alerts $40.60 +0.60 (+1.50%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$39.74▼$41.0550-Day Range$40.00▼$52.4452-Week Range$15.50▼$52.57Volume480,543 shsAverage Volume670,527 shsMarket Capitalization$2.44 billionP/E RatioN/ADividend YieldN/APrice Target$47.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Rhythm Pharmaceuticals alerts: Email Address Rhythm Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside16.7% Upside$47.40 Price TargetShort InterestBearish14.97% of Shares Sold ShortDividend StrengthN/ASustainability-1.80Upright™ Environmental ScoreNews Sentiment0.27Based on 7 Articles This WeekInsider TradingSelling Shares$4.11 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.03) to ($1.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.73 out of 5 starsMedical Sector481st out of 947 stocksPharmaceutical Preparations Industry227th out of 435 stocks 2.5 Analyst's Opinion Consensus RatingRhythm Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $47.40, Rhythm Pharmaceuticals has a forecasted upside of 16.7% from its current price of $40.60.Amount of Analyst CoverageRhythm Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted14.97% of the outstanding shares of Rhythm Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRhythm Pharmaceuticals has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.Change versus previous monthShort interest in Rhythm Pharmaceuticals has recently increased by 2.74%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRhythm Pharmaceuticals does not currently pay a dividend.Dividend GrowthRhythm Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRhythm Pharmaceuticals has received a 63.46% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Anti-obesity medication (A08)", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Rhythm Pharmaceuticals is -1.80. Previous Next 2.9 News and Social Media Coverage News SentimentRhythm Pharmaceuticals has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Rhythm Pharmaceuticals this week, compared to 5 articles on an average week.Search Interest2 people have searched for RYTM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows6 people have added Rhythm Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,105,895.00 in company stock.Percentage Held by InsidersOnly 4.70% of the stock of Rhythm Pharmaceuticals is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($4.03) to ($1.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rhythm Pharmaceuticals is -12.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rhythm Pharmaceuticals is -12.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRhythm Pharmaceuticals has a P/B Ratio of 14.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThey said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.There are five coins you must take a look at right away. About Rhythm Pharmaceuticals Stock (NASDAQ:RYTM)Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Read More RYTM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RYTM Stock News HeadlinesMarch 16, 2024 | finance.yahoo.comRYTM Dec 2024 40.000 putMarch 16, 2024 | finance.yahoo.comRYTM Apr 2024 70.000 callMarch 19, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:March 16, 2024 | finance.yahoo.comRYTM Jul 2024 22.500 putMarch 15, 2024 | msn.comRhythm Games With The Most Unique GameplayMarch 14, 2024 | yahoo.comBristol Rhythm AFC looking for sponsorship as inaugural season draws closerMarch 11, 2024 | globenewswire.comRhythm Pharmaceuticals Announces New Employment Inducement GrantsMarch 6, 2024 | globenewswire.comRhythm Pharmaceuticals Announces Participation at Upcoming Investor ConferencesMarch 19, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… March 3, 2024 | finance.yahoo.comRhythm Pharmaceuticals Full Year 2023 Earnings: Revenues DisappointMarch 2, 2024 | msn.comWATCH: ‘Rhythm City’s’ Suffocate ‘new look’ explainedFebruary 28, 2024 | msn.comInteractive Drumming Programs At Soulshine Rhythm ExperienceFebruary 24, 2024 | msn.comRhythm Pharmaceuticals (RYTM) Price Target Increased by 5.49% to 56.67February 24, 2024 | finance.yahoo.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportFebruary 23, 2024 | markets.businessinsider.comRhythm Pharmaceuticals: Expanding Markets and Innovation Fuel Buy Rating UpgradeFebruary 23, 2024 | finance.yahoo.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2023 Earnings Call TranscriptFebruary 23, 2024 | seekingalpha.comRhythm Pharmaceuticals: Action Too SpecificFebruary 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rhythm Pharmaceuticals Amid Strong Imcivree Performance and Market ExpansionFebruary 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rhythm Pharmaceuticals Amid Strong Prescription Growth and Promising Clinical DevelopmentsFebruary 22, 2024 | finanznachrichten.deRhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business UpdateFebruary 22, 2024 | finanznachrichten.deRhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in JapanFebruary 22, 2024 | markets.businessinsider.comRhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business UpdateFebruary 22, 2024 | msn.comRhythm Pharmaceuticals reports mixed Q4 results; initiates FY24 outlookFebruary 22, 2024 | finance.yahoo.comRhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business UpdateFebruary 22, 2024 | finance.yahoo.comRhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in JapanFebruary 22, 2024 | finance.yahoo.comRhythm Pharmaceuticals Inc (RYTM) Reports Q4 and Full Year 2023 Financial ResultsFebruary 22, 2024 | finance.yahoo.comRhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Misses Revenue EstimatesSee More Headlines Receive RYTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today3/18/2024Next Earnings (Estimated)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RYTM CUSIPN/A CIK1649904 Webwww.rhythmtx.com Phone(857) 264-4280Fax857-264-4299Employees177Year FoundedN/APrice Target and Rating Average Stock Price Target$47.40 High Stock Price Target$55.00 Low Stock Price Target$27.00 Potential Upside/Downside+16.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-184,680,000.00 Net Margins-238.50% Pretax Margin-237.79% Return on Equity-96.02% Return on Assets-55.02% Debt Debt-to-Equity RatioN/A Current Ratio5.58 Quick Ratio5.43 Sales & Book Value Annual Sales$77.43 million Price / Sales31.50 Cash FlowN/A Price / Cash FlowN/A Book Value$2.87 per share Price / Book14.13Miscellaneous Outstanding Shares60,140,000Free Float57,313,000Market Cap$2.44 billion OptionableOptionable Beta1.90 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. David P. Meeker M.D. (Age 70)Chairman, President & CEO Comp: $1.17MMr. Hunter C. Smith M.B.A. (Age 55)CFO & Treasurer Comp: $692.2kMr. Joseph Shulman (Age 49)Chief Technical Officer Comp: $608.2kMr. Yann Mazabraud (Age 51)Executive VP & Head of International Comp: $747.43kMs. Jennifer Lee (Age 48)Executive VP & Head of North America Comp: $644.2kMr. Christopher German (Age 53)Corporate Controller, Principal Accounting Officer & Executive Director Mr. David ConnollyHead of Investor Relations & Corporate CommunicationsMr. Jim FlahertySenior VP & General CounselMs. Sarah RyanVice President of Sales & MarketingMs. Pamela J. Cramer (Age 50)Chief Human Resources Officer More ExecutivesKey CompetitorsPTC TherapeuticsNASDAQ:PTCTKeros TherapeuticsNASDAQ:KROSTG TherapeuticsNASDAQ:TGTXRocket PharmaceuticalsNASDAQ:RCKTVera TherapeuticsNASDAQ:VERAView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 212,370 shares on 3/11/2024Ownership: 5.366%Wellington Management Group LLPBought 2,359 shares on 3/5/2024Ownership: 0.232%Perceptive Advisors LLCBought 1,773,282 shares on 2/26/2024Ownership: 3.645%Virtu Financial LLCBought 26,501 shares on 2/26/2024Ownership: 0.045%Quarry LPBought 1,500 shares on 2/20/2024Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions RYTM Stock Analysis - Frequently Asked Questions Should I buy or sell Rhythm Pharmaceuticals stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RYTM shares. View RYTM analyst ratings or view top-rated stocks. What is Rhythm Pharmaceuticals' stock price target for 2024? 5 brokerages have issued 1 year target prices for Rhythm Pharmaceuticals' shares. Their RYTM share price targets range from $27.00 to $55.00. On average, they anticipate the company's stock price to reach $47.40 in the next year. This suggests a possible upside of 16.7% from the stock's current price. View analysts price targets for RYTM or view top-rated stocks among Wall Street analysts. How have RYTM shares performed in 2024? Rhythm Pharmaceuticals' stock was trading at $45.97 at the beginning of the year. Since then, RYTM shares have decreased by 11.7% and is now trading at $40.60. View the best growth stocks for 2024 here. When is Rhythm Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our RYTM earnings forecast. How were Rhythm Pharmaceuticals' earnings last quarter? Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) posted its quarterly earnings results on Thursday, February, 22nd. The company reported ($0.70) earnings per share for the quarter, meeting the consensus estimate of ($0.70). The firm earned $24.23 million during the quarter, compared to analysts' expectations of $25.38 million. Rhythm Pharmaceuticals had a negative net margin of 238.50% and a negative trailing twelve-month return on equity of 96.02%. The firm's quarterly revenue was up 175.7% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.75) EPS. What ETFs hold Rhythm Pharmaceuticals' stock? ETFs with the largest weight of Rhythm Pharmaceuticals (NASDAQ:RYTM) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP).BlackRock Future Health ETF (BMED). What other stocks do shareholders of Rhythm Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), Kadmon (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT). When did Rhythm Pharmaceuticals IPO? (RYTM) raised $100 million in an initial public offering (IPO) on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen served as the underwriters for the IPO and Needham was co-manager. Who are Rhythm Pharmaceuticals' major shareholders? Rhythm Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (13.63%), Goldman Sachs Group Inc. (8.54%), Vanguard Group Inc. (5.46%), Vanguard Group Inc. (5.37%), Federated Hermes Inc. (3.91%) and Perceptive Advisors LLC (3.64%). Insiders that own company stock include David P Meeker, Hunter C Smith, Jennifer Chien, Jennifer Kayden Lee, Joseph Shulman, Pamela J Cramer, William T Roberts and Yann Mazabraud. View institutional ownership trends. How do I buy shares of Rhythm Pharmaceuticals? Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RYTM) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.